{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:58:18Z","timestamp":1791921498737,"version":"4.3.4"},"reference-count":54,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100010643","name":"Cidara Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010643","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Microbiol Spectr"],"published-print":{"date-parts":[[2023,6,15]]},"abstract":"<jats:p>Antifungal agents used to treat life-threatening infections are often associated with severe drug-drug interactions (DDIs) that may limit their usefulness. Rezafungin, a newly approved once-weekly echinocandin, has been shown to be free of DDIs based on extensive nonclinical and clinical testing described in this study.<\/jats:p>","DOI":"10.1128\/spectrum.01339-23","type":"journal-article","created":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T10:07:20Z","timestamp":1683540440000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":24,"title":["Absence of Clinically Meaningful Drug-Drug Interactions with Rezafungin: Outcome of Investigations"],"prefix":"10.1128","volume":"11","author":[{"given":"Shawn","family":"Flanagan","sequence":"first","affiliation":[{"name":"Cidara Therapeutics, Inc., San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Walker","sequence":"additional","affiliation":[{"name":"Mundipharma Ltd., Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8676-6717","authenticated-orcid":true,"given":"Voon","family":"Ong","sequence":"additional","affiliation":[{"name":"Cidara Therapeutics, Inc., San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Sandison","sequence":"additional","affiliation":[{"name":"Cidara Therapeutics, Inc., San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0007964"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.15620\/cdc:82532"},{"key":"e_1_3_3_4_2","volume-title":"Antibiotic resistance threats in the United States.","author":"Centers for Disease Control and Prevention","year":"2013","unstructured":"Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States. Centers for Disease Control and Prevention, Atlanta, GA. https:\/\/www.cdc.gov\/drugresistance\/pdf\/ar-threats-2013-508.pdf. Retrieved 5 April 2023."},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2022.2050224"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy358"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa502"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofv163"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2011.11.001"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2021.115627"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9120877"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S274872"},{"key":"e_1_3_3_13_2","volume-title":"Candida auris outbreak in healthcare facilities in northern Italy, 2019-2021.","author":"European Centre for Disease Prevention and Control","year":"2022","unstructured":"European Centre for Disease Prevention and Control. 2022. Candida auris outbreak in healthcare facilities in northern Italy, 2019-2021. European Centre for Disease Prevention and Control, Stockholm, Sweden."},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6901a2"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-014-2287-4"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01657-09"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00232-5"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1086\/598327"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2009.01820.x"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9080445"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9050227"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/jphp.12780"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ933"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02614-17"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01490-12"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-015-0758-3"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0401-8"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01582-16"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-018-2019-8"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa265"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx448"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit136"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw691"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.3390\/jof6040262"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1380"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2018.02.013"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00701-16"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.3390\/jof6040192"},{"key":"e_1_3_3_39_2","volume-title":"Cancidas 50 mg powder for concentrate for solution. Summary of product characteristics.","author":"Merck Sharp & Dohme Ltd","year":"2022","unstructured":"Merck Sharp & Dohme Ltd. 2022. Cancidas 50 mg powder for concentrate for solution. Summary of product characteristics. Merck Sharp & Dohme Ltd, London, United Kingdom. https:\/\/www.medicines.org.uk\/emc\/product\/2226. Retrieved 5 April 2023."},{"key":"e_1_3_3_40_2","volume-title":"Ecalta 100 mg powder for concentrate for solution for infusion. Summary of product characteristics.","author":"Pfizer Ltd","year":"2021","unstructured":"Pfizer Ltd. 2021. Ecalta 100 mg powder for concentrate for solution for infusion. Summary of product characteristics. Pfizer Ltd, Sandwich, United Kingdom. https:\/\/www.medicines.org.uk\/emc\/product\/454. Retrieved 5 April 2023."},{"key":"e_1_3_3_41_2","volume-title":"Mycamine 50 mg and 100 mg powder for concentrate for solution for infusion. Summary of product characteristics.","author":"Astellas Pharma Ltd","year":"2020","unstructured":"Astellas Pharma Ltd. 2020. Mycamine 50 mg and 100 mg powder for concentrate for solution for infusion. Summary of product characteristics. Astellas Pharma Ltd, Addlestone, United Kingdom. https:\/\/www.medicines.org.uk\/emc\/product\/7528\/smpc. Retrieved 5 April 2023."},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01627-16"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1038\/ja.2016.89"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.546"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01009-17"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00621-11"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv173"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02565-20"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01398-17"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00378-19"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.4.1331-1336.2005"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705398"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.2165\/11585270-000000000-00000"},{"key":"e_1_3_3_54_2","volume-title":"Caspofungin acetate for injection. US Prescribing Information.","author":"Fresenius Kabi USA LLC","year":"2021","unstructured":"Fresenius Kabi USA LLC. 2021. Caspofungin acetate for injection. US Prescribing Information. Fresenius Kabi USA LLC, Warrendale, PA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/206110lbl.pdf. Retrieved 26 April 2023."},{"key":"e_1_3_3_55_2","volume-title":"ICH harmonised guideline: integrated addendum to ICH E6(R1): guideline for good clinical practice E6(R2)","author":"International Council for Harmonisation (ICH)","year":"2016","unstructured":"International Council for Harmonisation (ICH). 2016. ICH harmonised guideline: integrated addendum to ICH E6(R1): guideline for good clinical practice E6(R2). https:\/\/database.ich.org\/sites\/default\/files\/E6_R2_Addendum.pdf. Retrieved 26 April 2023."}],"container-title":["Microbiology Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.01339-23","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.01339-23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T09:41:58Z","timestamp":1686822118000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/spectrum.01339-23"}},"subtitle":[],"editor":[{"given":"Matthew Zack","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6,15]]}},"alternative-id":["10.1128\/spectrum.01339-23"],"URL":"https:\/\/doi.org\/10.1128\/spectrum.01339-23","relation":{},"ISSN":["2165-0497"],"issn-type":[{"value":"2165-0497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,15]]},"assertion":[{"value":"2023-04-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01339-23"}}